Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study
Expert Review of Clinical Pharmacology · 04.03.2025 · 18 (3) · 175-183
DOI: 10.1080/17512433.2025.2465425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 11.02.2025. Verfasst von Abhirup Chatterjee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Nudix Hydrolases, Pyrophosphatases, Leukopenia, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Thiopurine S-methyltransferase (TPMT) and Nudix hydrolase (NUDT15) polymorphisms predispose to thiopurine-related leukopenia. METHODS: Retrospective evaluation of inflammatory bowel disease (IBD) patients harboring NUDT15 polymorphisms and exposed to thiopurines. We report the frequency of NUDT15 polymorphism, frequency of leukopenia, the tolerated dose of azathioprine, and the clinical efficacy of thiopurines. RESULTS: Of 1440 patients, 118 (8.2%) had NUDT15 polymorphism. Among 51 with complete details, 46 were heterozygous (90.2%), and 5 homozygous (9.2%) for NUDT15. Twenty (43.5%) heterozygous and all homozygous patients developed leukopenia. Leukopenia was significantly more in NUDT15 heterozygous group compared to controls (43.45% vs 7.8%, Odds ratio: 9, 95% CI 3.57-22.9). The maximum tolerated dose of azathioprine was lower in NUDT15 heterozygous group (1.1 ± 0.4 mg per kg vs 1.7 ± 0.7 mg per kg, p = 0.002). The mean time to leukopenia was earlier in the heterozygous group vs controls (19 ± 56 weeks vs 70 ± 53 weeks, p-value 0.002). Seven (35%) of 20 heterozygous patients who developed leukopenia, could be maintained at a lower dose of thiopurine. Twenty-five maintained clinical remission while on thiopurines. CONCLUSION: Thiopurines should be avoided in NUDT15 homozygous but can be used cautiously at lower dosages with frequent monitoring among heterozygous patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Pediatric Hemato-oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Abhirup Chatterjee, Prateek Bhatia, Saroj K Sinha, Harshal S Mandavdhare, Jimil Shah, Aravind Sekar, Minu Singh, Usha Dutta, Vishal Sharma
Zitieren
APA
Chatterjee, A., Bhatia, P., Sinha, S. K., Singh, A. K., Mandavdhare, H. S., Shah, J., Jearth, V., Sasani, A., Sekar, A., Singh, M., Dutta, U., & Sharma, V. (2025). Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study. Expert Review of Clinical Pharmacology, 18(3), 175-183. https://doi.org/10.1080/17512433.2025.2465425
Vancouver
Chatterjee A, Bhatia P, Sinha SK, Singh AK, Mandavdhare HS, Shah J, et al. Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study. Expert Review of Clinical Pharmacology. 2025;18(3):175-183. doi:10.1080/17512433.2025.2465425
BibTeX
@article{Chatterjee2025,
author = {Chatterjee, Abhirup and Bhatia, Prateek and Sinha, Saroj K and Singh, Anupam K and Mandavdhare, Harshal S and Shah, Jimil and Jearth, Vaneet and Sasani, Arpit and Sekar, Aravind and Singh, Minu and Dutta, Usha and Sharma, Vishal},
title = {Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
volume = {18},
number = {3},
pages = {175--183},
doi = {10.1080/17512433.2025.2465425}
}
EUVIMED